Harrow Health, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000QXWY44
HROW
Harrow Health, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Drug Manufacturers - Specialty & Generic
NAME
Harrow Health, Inc.
ISIN
US4158581094
TICKER
HROW
MIC
XNAS
REUTERS
HROW.OQ
BLOOMBERG
HROW US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Fri, 15.11.2024
Harrow Health
US4158581094
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences:
Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel)
November 19, 2024
1x1 Meetings Only
BTIG 4th Annual Ophthalmology Day (Virtual)
Dec...
Harrow Health
Wed, 13.11.2024
Harrow Health
US4158581094
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockh...
Harrow Health
Wed, 13.11.2024
Harrow Health
US4158581094
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (Nasdaq: GDRX), the l...
Harrow Health
Tue, 12.11.2024
Harrow Health
US4158581094
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025 Medicare Part D Prescription Drug Program. Starting January 1, 2025, VEVYE will be included in key formularies managed by major plan sponsors such as Express Scripts, Cigna, Kaiser Permanente, and CVS Carem...
Harrow Health
Thu, 07.11.2024
Harrow Health
US4158581094
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a leading provider of specialty pharmacy and patient support hub services. This multi-year exclusive partnership is designed to expand access to Harrow’s ophth...
Harrow Health
Thu, 31.10.2024
Harrow Health
US4158581094
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its webs...
Harrow Health
Thu, 10.10.2024
Harrow Health
US4158581094
Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced the dosing of the last patient in its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT‑300, a non-IV, non-opioid tablet for procedural sedation during cataract...
Harrow Health
Thu, 03.10.2024
Harrow Health
US4158581094
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative‑free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocul...
Harrow Health
Wed, 25.09.2024
Harrow Health
US4158581094
Tennessee Governor Bill Lee, Department of Economic and Community Development Commissioner Stuart C. McWhorter, and Mark L. Baum, Chief Executive Officer of Harrow, Inc. (Nasdaq: HROW), announced today that Harrow is expanding its corporate headquarters in Nashville.
Harrow was originally founded in 2012 in San Diego, California. In 2019, Harrow ...
Harrow Health
Tue, 03.09.2024
Harrow Health
US4158581094
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York:
H.C. Wainwright 26th Annual Global Investment Conference (Lotte New York Palace Hotel)
September 9-11, 2024
Company will present at 8:00 a.m. ET on ...
Harrow Health
Information on product placements
